Tranzyme Pharma Presents Data Demonstrating that TZP-101 (Ulimorelin) Restores Bowel Function in Patients with Postoperative Ileus (POI) Regardless of the Extent of Opioid Use

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Tranzyme Pharma today announced that Philippa Charlton, MD, Tranzyme’s Medical Director, and her colleagues G. Bochicchio, J.C. Pezullo, G. Kosutic, and A. Senagore, will present a poster entitled “The Prokinetic Agent TZP-101 (a Ghrelin Agonist) Accelerates GI Recovery in Partial Colectomy Patients Independently of Total Opioid Use and Type of Surgery” at the upcoming 2010 Annual Scientific Meeting of the American Society of Colon and Rectal Surgeons (ASCRS; Minneapolis, May 15-19). The poster session will be held on Tuesday, May 18th in Exhibit Hall B of the Minneapolis Convention Center.

MORE ON THIS TOPIC